Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
15.26
Dollar change
-0.04
Percentage change
-0.26
%
IndexRUT P/E- EPS (ttm)-4.70 Insider Own10.55% Shs Outstand12.18M Perf Week-14.37%
Market Cap185.37M Forward P/E- EPS next Y-5.66 Insider Trans26.43% Shs Float10.89M Perf Month-19.30%
Income-38.70M PEG- EPS next Q-1.24 Inst Own95.55% Short Float22.05% Perf Quarter-71.05%
Sales0.00M P/S- EPS this Y58.20% Inst Trans13.43% Short Ratio3.63 Perf Half Y-65.42%
Book/sh12.36 P/B1.23 EPS next Y-31.32% ROA-38.61% Short Interest2.40M Perf Year156.90%
Cash/sh13.14 P/C1.16 EPS next 5Y- ROE-51.32% 52W Range4.94 - 61.90 Perf YTD152.65%
Dividend Est.- P/FCF- EPS past 5Y18.86% ROI-25.37% 52W High-75.35% Beta2.58
Dividend TTM- Quick Ratio13.84 Sales past 5Y76.56% Gross Margin- 52W Low209.08% ATR (14)1.17
Dividend Ex-Date- Current Ratio13.84 EPS Y/Y TTM58.00% Oper. Margin- RSI (14)31.89 Volatility7.58% 6.39%
Employees19 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price56.78
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q49.52% Payout- Rel Volume0.51 Prev Close15.30
Sales Surprise- EPS Surprise-20.81% Sales Q/Q- EarningsNov 07 BMO Avg Volume661.11K Price15.26
SMA20-11.24% SMA50-14.58% SMA200-60.38% Trades Volume333,916 Change-0.26%
Date Action Analyst Rating Change Price Target Change
Dec-02-24Initiated Piper Sandler Overweight
Jul-30-24Initiated Wedbush Outperform $85
Jul-22-24Resumed H.C. Wainwright Buy $80
Jun-26-24Initiated B. Riley Securities Buy $85
Jun-03-24Reiterated Oppenheimer Outperform $60 → $80
May-13-24Initiated RBC Capital Mkts Outperform $77
Mar-06-24Upgrade Jefferies Hold → Buy $4 → $46
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Dec-04-24 12:31PM
Dec-03-24 07:00AM
Nov-26-24 06:54AM
Nov-21-24 08:00AM
Nov-12-24 08:00AM
07:28AM Loading…
Nov-07-24 07:28AM
07:00AM
Nov-04-24 04:10PM
07:00AM
Oct-29-24 08:00AM
Oct-16-24 08:00AM
Oct-15-24 07:02PM
Oct-11-24 07:02PM
Oct-03-24 05:07AM
Sep-26-24 08:00AM
09:41PM Loading…
Sep-24-24 09:41PM
Sep-20-24 03:18PM
Sep-12-24 07:59AM
Sep-05-24 08:00AM
Sep-04-24 07:29PM
Sep-02-24 05:22PM
Aug-27-24 08:03PM
Aug-26-24 09:55AM
Aug-21-24 05:00AM
Aug-20-24 08:00AM
Aug-09-24 12:00PM
09:55AM
Aug-06-24 08:08AM
08:00AM
Jul-30-24 08:50AM
11:13AM Loading…
Jul-01-24 11:13AM
Jun-30-24 10:13AM
Jun-01-24 10:00AM
May-30-24 08:00AM
May-23-24 05:05PM
May-17-24 04:12PM
May-09-24 08:00AM
May-07-24 01:52PM
08:17AM
08:00AM
May-06-24 02:06PM
May-01-24 08:00AM
Apr-24-24 04:05PM
Apr-19-24 02:30PM
Apr-16-24 08:50AM
Apr-12-24 06:40AM
Apr-02-24 08:00AM
Mar-15-24 08:50AM
Mar-14-24 09:38AM
Mar-12-24 08:21AM
08:00AM
Mar-06-24 08:00AM
Feb-28-24 08:00AM
Feb-06-24 09:50AM
Feb-02-24 04:01PM
Jan-31-24 09:19AM
Jan-30-24 06:55PM
Jan-29-24 06:57AM
Jan-26-24 07:30AM
Jan-23-24 08:00AM
Jan-09-24 08:00AM
Dec-18-23 08:00AM
Dec-01-23 09:40AM
Nov-07-23 09:56AM
08:11AM
08:00AM
Nov-02-23 08:00AM
Oct-17-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 09:05AM
Sep-19-23 08:00AM
Aug-08-23 09:08AM
08:00AM
Jul-31-23 08:00AM
Jul-26-23 05:11PM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-30-23 08:45PM
May-09-23 08:11AM
08:00AM
May-01-23 08:00AM
Apr-18-23 08:00AM
Apr-17-23 08:30AM
Mar-14-23 04:35PM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-13-23 11:27AM
06:55AM
Nov-10-22 09:05AM
Nov-08-22 08:05AM
Nov-03-22 05:00PM
Oct-14-22 08:05AM
Sep-26-22 08:05AM
Sep-22-22 08:00AM
Sep-12-22 07:00AM
Aug-09-22 09:25AM
08:00AM
May-11-22 08:00AM
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormorant Asset Management, LP10% OwnerSep 20 '24Buy20.01350,0007,003,7612,375,000Sep 24 04:04 PM
CATLIN AVERY WDirectorSep 04 '24Proposed Sale56.4388850,109Sep 04 04:44 PM
Moran Sean F.Chief Financial OfficerJun 17 '24Option Exercise14.106,73094,89355,335Jun 18 05:59 PM
Moran Sean F.Chief Financial OfficerJun 14 '24Option Exercise8.579,35580,18756,393Jun 18 05:59 PM
Moran Sean F.Chief Financial OfficerJun 18 '24Option Exercise30.001,95858,74050,563Jun 18 05:59 PM
Moran Sean F.Chief Financial OfficerJun 14 '24Sale49.879,355466,56948,605Jun 18 05:59 PM
Moran Sean F.Chief Financial OfficerJun 17 '24Sale46.776,730314,78948,605Jun 18 05:59 PM
Moran Sean F.Chief Financial OfficerJun 18 '24Sale42.121,95882,47948,605Jun 18 05:59 PM
Cohen YuvalChief Executive OfficerJun 18 '24Option Exercise24.4215,759384,85996,067Jun 18 05:58 PM
Cohen YuvalChief Executive OfficerJun 14 '24Option Exercise9.9129,317290,498101,230Jun 18 05:58 PM
Cohen YuvalChief Executive OfficerJun 17 '24Option Exercise25.9011,103287,53093,733Jun 18 05:58 PM
Cohen YuvalChief Executive OfficerJun 14 '24Sale50.1729,3171,470,72284,400Jun 18 05:58 PM
Cohen YuvalChief Executive OfficerJun 18 '24Sale42.2422,938968,83277,221Jun 18 05:58 PM
Cohen YuvalChief Executive OfficerJun 17 '24Sale46.0211,103510,96384,400Jun 18 05:58 PM
HOLMER ALAN FDirectorJun 14 '24Option Exercise30.001,66750,0105,829Jun 14 04:24 PM
Moran Sean F.Chief Financial OfficerApr 10 '24Option Exercise30.001,78753,61048,605Apr 11 09:17 AM
Cormorant Asset Management, LP10% OwnerMar 08 '24Buy44.38300,00013,314,1932,025,000Mar 11 05:34 PM
Cormorant Asset Management, LP10% OwnerMar 07 '24Buy40.05250,00010,013,3671,725,000Mar 11 05:34 PM
Cormorant Asset Management, LP10% OwnerFeb 02 '24Buy19.00750,00014,250,0001,475,000Feb 06 04:00 PM
HOLMER ALAN FDirectorJan 26 '24Option Exercise4.976293,1261,379Jan 30 06:07 PM
Cohen YuvalChief Executive OfficerJan 26 '24Option Exercise4.977,17935,6807,179Jan 30 04:56 PM
Cormorant Asset Management, LP10% OwnerJan 26 '24Buy32.24282,6329,111,941725,000Jan 30 04:23 PM